Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 101-110 of 525 results
Dose-Response: An International Journal, 2022 • October 1, 2022
This study used iTRAQ proteomics to investigate the molecular mechanisms of hyperbaric oxygen therapy (HBOT) in a rat model of spinal cord injury (SCI). The study identified differentially expressed p...
KEY FINDING: HBOT influences biological processes such as oxygen transport, gas transport and regulation of T cell proliferation.
Spinal Cord Series and Cases, 2021 • January 1, 2021
This retrospective study analyzed data from the Rochester Epidemiology Project to determine the prevalence of cholesterol-lowering agent use after SCI and its impact on motor function recovery. The st...
KEY FINDING: 30% of individuals with SCI had a prescription for a cholesterol-lowering agent.
Cell Death & Disease, 2020 • July 10, 2020
This study investigated the therapeutic effects of RAPA and decompression, in combination or separately, on the histopathology of the injured spinal cord in a rabbit model of SCI. The combination ther...
KEY FINDING: Combination therapy (rapamycin and surgical decompression) significantly reduced intramedullary pressure (IMP) and inhibited apoptosis after SCI.
BMC Neurology, 2020 • January 20, 2020
The study examined healthcare providers' experiences with medication therapy management (MTM) for individuals with spinal cord injury/dysfunction (SCI/D). Participants discussed their experiences and ...
KEY FINDING: Healthcare providers generally felt that caring for SCI/D patients was similar to caring for other patients, but with added complexity due to physical limitations. Most participants felt that the care they provided for persons with SCI/D was similar to the care that they provided to other patients, with some differences relating to the physical limitations and medical complexity associated with SCI/D.
Neurotrauma Reports, 2021 • January 1, 2021
This study evaluated the adverse effects of high-dose methylprednisolone (MP) administration on bone loss after acute spinal cord injury (SCI) in rats. The results showed that MP significantly reduced...
KEY FINDING: High-dose MP administration significantly reduced bone mineral density (BMD) in the distal femur and proximal tibia of SCI rats compared to SCI-vehicle animals.
Evidence-Based Complementary and Alternative Medicine, 2022 • October 7, 2022
This study investigates the analgesic effects of electroacupuncture (EA) on neuropathic pain in a chronic constriction injury (CCI) rat model. The research focuses on the role of GABAA receptors and m...
KEY FINDING: EA treatment relieves mechanical allodynia and thermal hyperalgesia in CCI rats, as demonstrated by increased MWT and TWL values compared to the CCI group.
Molecular Pain, 2021 • February 4, 2021
This study investigates the potential of electroacupuncture (EA) to alleviate neuropathic pain by suppressing P2X7R expression in a rat model of spinal nerve ligation (SNL). The research aims to under...
KEY FINDING: EA treatment increased pain threshold in SNL rats, indicating pain relief, while the P2X7R agonist BzATP suppressed this EA-induced increase.
JBMR Plus, 2020 • August 1, 2020
This study evaluated the effectiveness of denosumab in preserving bone mineral density (BMD) in individuals with subacute spinal cord injury (SCI). The findings indicate that denosumab maintained BMD ...
KEY FINDING: Denosumab maintained aBMD at the distal femur and proximal tibia in persons with a subacute motor-complete SCI.
JOURNAL OF NEUROTRAUMA, 2014 • August 1, 2014
This study evaluated the acute effects of serotonergic medications on locomotor performance in individuals with incomplete spinal cord injury (iSCI). The study found that administration of a 5HT antag...
KEY FINDING: Neither SSRIs nor 5HT antagonists improved locomotion in iSCI subjects.
The Journal of Spinal Cord Medicine, 2015 • January 1, 2015
This retrospective study investigated the protective effect of oral alendronate (ALN) intake on the appearance of heterotopic ossification (HO) in patients with spinal cord injury (SCI). The study fou...
KEY FINDING: There was no statistically significant difference in the incidence of HO in patients receiving oral ALN compared to those not receiving it.